| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Feb―22 |
Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis |
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink |
| 2 |
[GO] |
2024―Nov―20 |
A theoretical systems chronopharmacology approach for COVID-19: Modeling circadian regulation of lung infection and potential precision therapies |
Yu-Yao Tseng |
| 3 |
[GO] |
2024―Jun―05 |
Joint modeling of monocyte HLA-DR expression trajectories predicts 28-day mortality in severe SARS-CoV-2 patients |
Gaelle Baudemont, Coralie Tardivon, Guillaume Monneret, Martin Cour, Thomas Rimmelé, Lorna Garnier, Hodane Yonis, Jean-Christophe Richard, Remy Coudereau, Morgane Gossez, Florent Wallet, Marie-Charlotte Delignette, Frederic Dailler, Marielle Buisson, Anne-Claire Lukaszewicz, Laurent Argaud, Cédric Laouenan, Julie Bertrand, Fabienne Venet |
| 4 |
[GO] |
2024―May―24 |
Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer |
Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota |
| 5 |
[GO] |
2023―Nov―11 |
Machine Learning-based Integration of Network Features and Chemical Structure of Compounds for SARS-CoV-2 Drug Effect Analysis |
Julian Späth, Rui-Sheng Wang, Maeve Humphrey, Jan Baumbach, Joseph Loscalzo |
| 6 |
[GO] |
2023―Oct―06 |
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals |
Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L. Brown, Matthew G. Johnson, Amanda Paschke, Matthew L. Rizk, Julie A. Stone |
| 7 |
[GO] |
2023―Sep―20 |
Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients |
Nadège Néant, Guillaume Lingas, Alexandre Gaymard, Drifa Belhadi, Maya Hites, Thérèse Staub, Richard Greil, Jose-Artur Paiva, Julien Poissy, Nathan Peiffer-Smadja, Dominique Costagliola, Yazdan Yazdanpanah, Maude Bouscambert-Duchamp, Amandine Gagneux-Brunon, Florence Ader, France Mentré, Florent Wallet, Charles Burdet, Jérémie Guedj |
| 8 |
[GO] |
2023―Sep―16 |
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans |
Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz-Guiñazú, Juan José Pérez-Ruixo |
| 9 |
[GO] |
2023―Aug―03 |
SARS-CoV-2 viral dynamic modelling to inform model selection and timing and efficacy of antiviral therapy |
Shengyuan Zhang, Akosua A. Agyeman, Christoforos Hadjichrysanthou, Joseph F. Standing |
| 10 |
[GO] |
2023―Jul―04 |
Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modelling |
Rob C. van Wijk, Laurynas Mockeliunas, Caryn M. Upton, Jonathan Peter, Andreas H. Diacon, Ulrika S. H. Simonsson |
| 11 |
[GO] |
2022―Apr―12 |
Quantitative Methods and Modeling to Assess
COVID-19-Interrupted
in vivo Pharmacokinetic Bioequivalence Studies with Two Reference Batches |
Yuqing Gong, Kairui Feng, Peijue Zhang, Jieon Lee, Yuzhuo Pan, Zhen Zhang, Zhanglin Ni, Tao Bai, Miyoung Yoon, Bing Li, Carol Y. Kim, Lanyan Fang, Liang Zhao |
| 12 |
[GO] |
2022―Mar―15 |
PK/PD Modelling Links Accelerated Resolution of COVID-19-Related Clinical Symptoms to SARS-CoV-2 Viral Load Reduction in Patients Following Treatment with Bamlanivimab Alone or Bamlanivimab and Etesevimab Together |
C. Steven Ernest, Jenny Y. Chien, Dipak R. Patel, Emmanuel Chigutsa |
| 13 |
[GO] |
2021―Nov―18 |
Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction |
Asami Sukeishi, Kotaro Itohara, Atsushi Yonezawa, Yuki Sato, Katsuyuki Matsumura, Yoshiki Katada, Takayuki Nakagawa, Satoshi Hamada, Naoya Tanabe, Eishi Imoto, Shinichi Kai, Toyohiro Hirai, Motoko Yanagita, Shigeru Ohtsuru, Tomohiro Terada, Isao Ito |
| 14 |
[GO] |
2021―Oct―06 |
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCovid - imatinib - study |
Imke H. Bartelink, Pierre M. Bet, Nicolas Widmer, Monia Guidi, Erik Duijvelaar, Bram Grob, Richard Honeywell, Amanda Evelo, Ivo P. E. Tielbeek, Sue D Snape, Henrike Hamer, Laurent A. Decosterd, Harm Jan Bogaard, Jurjan Aman, Eleonora L. Swart |
| 15 |
[GO] |
2021―Jul―31 |
Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines |
Mario Giorgi, Rajat Desikan, Piet H. Graaf, Andrzej M. Kierzek |
| 16 |
[GO] |
2021―Jul―22 |
Population Pharmacokinetics of Favipiravir in Patients with COVID-19 |
Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Keisuke Tomii, Tohru Hashida |
| 17 |
[GO] |
2020―Dec―10 |
A Mechanism-based Pharmacokinetic Model of Remdesivir Leveraging Interspecies Scaling to Simulate COVID-19 Treatment in Humans |
Patrick O. Hanafin, Brian Jermain, Anthony J. Hickey, Alexander V. Kabanov, Angela D. Kashuba, Timothy P. Sheahan, Gauri G. Rao |
| 18 |
[GO] |
2020―Nov―21 |
A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development |
Wei Dai, Rohit Rao, Anna Sher, Nessy Tania, Cynthia J. Musante, Richard Allen |
| 19 |
[GO] |
2020―Nov―18 |
Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions |
Meera Varshneya, Itziar Irurzun-Arana, Chiara Campana, Rafael Dariolli, Amy Gutierrez, Taylor K. Pullinger, Eric A. Sobie |
| 20 |
[GO] |
2020―Jul―23 |
Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties |
Daniel Scholes Rosenbloom, Ping Zhao, Vikram Sinha |
| 21 |
[GO] |
2020―Jun―18 |
Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load |
Antonio Gonçalves, Julie Bertrand, Ruian Ke, Emmanuelle Comets, Xavier de Lamballerie, Denis Malvy, Andrés Pizzorno, Olivier Terrier, Manuel Rosa Calatrava, France Mentré, Patrick Smith, Alan S Perelson, Jérémie Guedj |
| 22 |
[GO] |
2020―Jun―08 |
Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials |
Jim H. Hughes, Kevin Sweeney, Sima Ahadieh, Daniele Ouellet |
| 23 |
[GO] |
2020―May―29 |
Salvaging CNS Clinical Trials halted due to COVID-19 |
Hugo Geerts, Piet H. van der Graaf |
|
